WHO ICTRP trial
Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer
EUCTR2019-001745-40-PL · EU Clinical Trials Register · Not Recruiting
Key facts
| Trial ID | EUCTR2019-001745-40-PL |
|---|---|
| Public title | Olaparib in combination with pembrolizumab in HRRm and HRD positive cancer |
| Scientific title | A Phase 2 Study of Olaparib in Combination with Pembrolizumab in Participants with Previously Treated, Homologous Recombination Repair Mutation (HRRm) and/or Homologous Recombination Deficiency (HRD)-Positive Advanced Cancer - Olaparib in combination with pembrolizumab in HRRm and HRD positive… |
| Primary sponsor | Merck Sharp & Dohme LLC |
| Registry | EU Clinical Trials Register |
| Recruitment status | Not Recruiting |
| Study type | Interventional clinical trial of medicinal product |
| Phase | Human pharmacology (Phase I): no Therapeutic exploratory (Phase II): yes Therapeutic confirmatory - (Phase III): no Therapeutic use (Phase IV): no |
| Countries | Colombia;Argentina;Puerto Rico;Romania;United States;Ukraine;Spain;Canada;Latvia;Sweden;Turkey;Poland;Guatemala;Korea, Republic of;Mexico;South Africa;Italy;Israel;Australia;France;Peru;Germany |
| Conditions | HRRm and/or HRD-positive cancer MedDRA version: 21.1 Level: LLT Classification code 10065252 Term: Solid tumor System Organ Class: 100000004864 ;Therapeutic area: Diseases [C] - Cancer [C04] |
| Interventions | Product Name: PEMBROLIZUMAB Product Code: MK-3475 Pharmaceutical Form: Solution for infusion INN or Proposed INN: PEMBROLIZUMAB CAS Number: 1374853-91-4 Current Sponsor code: MK-3475 Concentration unit: mg/ml milligram(s)/millilitre… |
| Registration date | Mar 10, 2019 |
| Target size | 300 |
| Secondary IDs | MK-7339-007;142968 |
| Registry page | clinicaltrialsregister.eu |
At a glance
- No Results available
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About WHO ICTRP trial registrations
The WHO ICTRP combines trial registrations from primary registries worldwide into a single searchable index. Contact and ethics-committee details are not shown here.
Source: World Health Organization (WHO), International Clinical Trials Registry Platform (ICTRP) · Source date: